{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:23:43Z","timestamp":1791944623431,"version":"4.3.4"},"reference-count":39,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We examined adults with untreated Burkitt lymphoma (BL) from 2009 to 2018 across 30 US cancer centers. Factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox models. Among 641 BL patients, baseline features included the following: median age, 47 years; HIV+, 22%; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 to 4, 23%; &amp;gt;1 extranodal site, 43%; advanced stage, 78%; and central nervous system (CNS) involvement, 19%. Treatment-related mortality was 10%, with most common causes being sepsis, gastrointestinal bleed\/perforation, and respiratory failure. With 45-month median follow-up, 3-year PFS and OS rates were 64% and 70%, respectively, without differences by HIV status. Survival was better for patients who received rituximab vs not (3-year PFS, 67% vs 38%; OS, 72% vs 44%; P &amp;lt; .001) and without difference based on setting of administration (ie, inpatient vs outpatient). Outcomes were also improved at an academic vs community cancer center (3-year PFS, 67% vs 46%, P = .006; OS, 72% vs 53%, P = .01). In multivariate models, age \u2265 40 years (PFS, hazard ratio [HR] = 1.70, P = .001; OS, HR = 2.09, P &amp;lt; .001), ECOG PS 2 to 4 (PFS, HR = 1.60, P &amp;lt; .001; OS, HR = 1.74, P = .003), lactate dehydrogenase &amp;gt; 3\u00d7 normal (PFS, HR = 1.83, P &amp;lt; .001; OS, HR = 1.63, P = .009), and CNS involvement (PFS, HR = 1.52, P = .017; OS, HR = 1.67, P = .014) predicted inferior survival. Furthermore, survival varied based on number of factors present (0, 1, 2 to 4 factors) yielding 3-year PFS rates of 91%, 73%, and 50%, respectively; and 3-year OS rates of 95%, 77%, and 56%, respectively. Collectively, outcomes for adult BL in this real-world analysis appeared more modest compared with results of clinical trials and smaller series. In addition, clinical prognostic factors at diagnosis identified patients with divergent survival rates.<\/jats:p>","DOI":"10.1182\/blood.2020006926","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:39:13Z","timestamp":1611247153000},"page":"374-386","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sperling","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington\/Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-2998","authenticated-orcid":false,"given":"Seo-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Rush University Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Vaca","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Wei","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rector","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"D'Angelo","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Carbone Cancer Center, University of Wisconsin, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Hematology, James Cancer Center, The Ohio State University Hospital, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Berg","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Loyola University Medical Center, Maywood, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Churnetski","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Winship Cancer Institute, Emory University Medical Center, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-4442","authenticated-orcid":false,"given":"Amandeep","family":"Godara","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyong","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-3867","authenticated-orcid":false,"given":"Maryam","family":"Yazdy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rabinovich","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-9170","authenticated-orcid":false,"given":"Gaurav","family":"Varma","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-4883","authenticated-orcid":false,"given":"Agrima","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6059-1389","authenticated-orcid":false,"given":"Malvi","family":"Savani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-0564","authenticated-orcid":false,"given":"Madelyn","family":"Burkart","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ren","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allandria","family":"Straker-Edwards","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Winship Cancer Institute, Emory University Medical Center, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten Marie","family":"Boughan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-3221","authenticated-orcid":false,"given":"Scott E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Loyola University Medical Center, Maywood, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-0615","authenticated-orcid":false,"given":"Brad M.","family":"Haverkos","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Colorado, Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Orellana-Noia","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Carbone Cancer Center, University of Wisconsin, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-2069","authenticated-orcid":false,"given":"Adam","family":"Zayac","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Brown University, Providence, RI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ramdial","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4774-806X","authenticated-orcid":false,"given":"Seth M.","family":"Maliske","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology, James Cancer Center, The Ohio State University Hospital, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Venugopal","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Rush University Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington\/Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Stadnik","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Naik","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Nebraska, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caimi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Colorado, Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Palmisiano","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Thomas Jefferson University Hospital, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-8345","authenticated-orcid":false,"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Brown University, Providence, RI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2021012116213987100_B1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021012116213987100_B2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2021012116213987100_B3","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2021012116213987100_B4","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"12","key":"2021012116213987100_B5","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","article-title":"A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt\u2019s lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"2021012116213987100_B6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2021012116213987100_B7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2021012116213987100_B8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"issue":"26","key":"2021012116213987100_B9","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2021012116213987100_B10","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divin\u00e9","year":"2005","journal-title":"Ann Oncol"},{"issue":"20","key":"2021012116213987100_B11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"10036","key":"2021012116213987100_B12","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"2021012116213987100_B13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2021012116213987100_B14","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"issue":"5","key":"2021012116213987100_B15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021012116213987100_B16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"5","key":"2021012116213987100_B17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(03)00047-7","article-title":"Internal and external validation of predictive models: a simulation study of bias and precision in small samples","volume":"56","author":"Steyerberg","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2021012116213987100_B18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2021012116213987100_B19","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, vol. XXV","author":"Harrell","year":"2015"},{"issue":"16","key":"2021012116213987100_B20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/sim.4780111607","article-title":"A bootstrap resampling procedure for model building: application to the Cox regression model","volume":"11","author":"Sauerbrei","year":"1992","journal-title":"Stat Med"},{"issue":"1","key":"2021012116213987100_B21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"issue":"suppl 1","key":"2021012116213987100_B22","doi-asserted-by":"crossref","first-page":"402a","DOI":"10.1182\/blood-2019-122990","article-title":"Outcomes of patients with newly-diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: a multi-institutional real-world analysis","volume":"134","author":"Zayac","year":"2019","journal-title":"Blood"},{"key":"2021012116213987100_B23","first-page":"S239","article-title":"Characteristics and outcomes of HIV-related Burkitt lymphoma (HIV-BL) in the post-rituximab era across 30 US cancer centers","volume":"295059","author":"Alderuccio","year":"2020","journal-title":"HemaSphere","ISSN":"https:\/\/id.crossref.org\/issn\/2572-9241","issn-type":"print"},{"issue":"19","key":"2021012116213987100_B24","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"key":"2021012116213987100_B25","article-title":"Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy [published online ahead of print 7 April 2020]","author":"Zayac","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2021012116213987100_B26","first-page":"188","article-title":"Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R","volume":"130","author":"Roschewski","year":"2017","journal-title":"Blood"},{"key":"2021012116213987100_B27","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma [published online ahead of print 26 May 2020]","author":"Roschewski","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021012116213987100_B28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","article-title":"Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens","volume":"97","author":"Oosten","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"2021012116213987100_B29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15262","article-title":"Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M\/IVAC plus or minus rituximab","volume":"181","author":"Zhu","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2021012116213987100_B30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/10428194.2019.1654097","article-title":"Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma","volume":"61","author":"Decker","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2021012116213987100_B31","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2021012116213987100_B32","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"24","key":"2021012116213987100_B33","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2012-12-475558","article-title":"Trends in survival of patients with Burkitt lymphoma\/leukemia in the USA: an analysis of 3691 cases","volume":"121","author":"Costa","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2021012116213987100_B34","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2021012116213987100_B35","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"issue":"4","key":"2021012116213987100_B36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.16425","article-title":"Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients","volume":"189","author":"Jakobsen","year":"2020","journal-title":"Br J Haematol"},{"issue":"20","key":"2021012116213987100_B37","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"key":"2021012116213987100_B38","unstructured":"National Comprehensive Cancer Network\n          . (2020). B-cell lymphomas (version 1.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 6 April 2020."},{"issue":"15 suppl","key":"2021012116213987100_B39","article-title":"Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites","volume":"38","author":"Olszewski","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/374\/1797623\/bloodbld2020006926.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/374\/1797623\/bloodbld2020006926.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:39:19Z","timestamp":1611247159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/3\/374\/461327\/Burkitt-lymphoma-in-the-modern-era-real-world"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020006926","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}